ConductScience.org, home

Paper42836780PubMed

Autoantibodies neutralizing type I interferons in COVID-19 patients from southern Brazil.

Sbruzzi RC and 17 others. J Hum Immun, 2026.

Cite this record

ConductScience Library. Autoantibodies neutralizing type I interferons in COVID-19 patients from southern Brazil. Papers, record 42836780. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42836780

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Autoantibodies neutralizing type I interferons in COVID-19 patients from southern Brazil.
Journal
J Hum Immun
Year
2026
Publication types
Journal Article
Revised in PubMed
2026-10-08

Source PubMed

Authors18

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants5

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
2020-0479Hospital de Clínicas de Porto AlegrePubMed
518211/2020-00Coordenação de Aperfeiçoamento de Pessoal de Nível SuperiorPubMed
937823/2024-00Coordenação de Aperfeiçoamento de Pessoal de Nível SuperiorPubMed
ANR-2021-RUS-008French National Research AgencyPubMed
3110092025-5Conselho Nacional de Desenvolvimento Científico e TecnológicoPubMed

Source PubMed

Download CSV of grants

References87

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
136434007Defective activation and regulation of type I interferon immunity is associated with increasing COVID-19 severity.Nat Commun2022https://conductscience.org/library/papers/36434007PubMed
232972995Inborn errors of type I IFN immunity in patients with life-threatening COVID-19.Science2020https://conductscience.org/library/papers/32972995PubMed
335419822Anti-IFN-α/-ω neutralizing antibodies from COVID-19 patients correlate with downregulation of IFN response and laboratory biomarkers of disease severity.Eur J Immunol2022https://conductscience.org/library/papers/35419822PubMed
435576468The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies.Proc Natl Acad Sci U S A2022https://conductscience.org/library/papers/35576468PubMed
536342455Human type I IFN deficiency does not impair B cell response to SARS-CoV-2 mRNA vaccination.J Exp Med2023https://conductscience.org/library/papers/36342455PubMed
641623353Autoantibodies neutralizing type 1 interferons in two cohorts of people with HIV.J Hum Immun2026https://conductscience.org/library/papers/41623353PubMed
738129345Chest Computed Tomography Characteristics of Critically Ill COVID-19 Patients with Auto-antibodies Against Type I Interferons.J Clin Immunol2023https://conductscience.org/library/papers/38129345PubMed
834767118Interferon-α2 Auto-antibodies in Convalescent Plasma Therapy for COVID-19.J Clin Immunol2022https://conductscience.org/library/papers/34767118PubMed
941332446Human immunity.J Hum Immun2025https://conductscience.org/library/papers/41332446PubMed
1038547583Salivary autoantibodies to type I IFNs: Mirror plasma levels, predispose to severe COVID-19, and enhance feasibility for clinical screening.Heart Lung2024https://conductscience.org/library/papers/38547583PubMed
1134010947Diverse functional autoantibodies in patients with COVID-19.Nature2021https://conductscience.org/library/papers/34010947PubMed
1237698062Examination of autoantibodies to type I interferon in patients suffering from long COVID.J Med Virol2023https://conductscience.org/library/papers/37698062PubMed
1338193358Human autoantibodies neutralizing type I IFNs: From 1981 to 2023.Immunol Rev2024https://conductscience.org/library/papers/38193358PubMed
1441394891Prevalence and association of type I IFN autoantibodies with clinical outcomes in critically ill Brazilian COVID-19 patients.J Hum Immun2025https://conductscience.org/library/papers/41394891PubMed
1536113674Genetic and immunologic evaluation of children with inborn errors of immunity and severe or critical COVID-19.J Allergy Clin Immunol2022https://conductscience.org/library/papers/36113674PubMed
1637906115High Anti-Interferon-Alpha Autoantibody Levels in Severe/Critical COVID-19 Patients from Peru.J Interferon Cytokine Res2023https://conductscience.org/library/papers/37906115PubMed
1738231281Evaluation of Genetic or Cellular Impairments in Type I IFN Immunity in a Cohort of Young Adults with Critical COVID-19.J Clin Immunol2024https://conductscience.org/library/papers/38231281PubMed
1832405102A Global Effort to Define the Human Genetics of Protective Immunity to SARS-CoV-2 Infection.Cell2020https://conductscience.org/library/papers/32405102PubMed
1938226654Human genetic determinants of COVID-19 in Brazil: challenges and future plans.Genet Mol Biol2024https://conductscience.org/library/papers/38226654PubMed
2034960822Microarray-Based Detection of Antibodies against SARS-CoV-2 Proteins, Common Respiratory Viruses and Type I Interferons.Viruses2021https://conductscience.org/library/papers/34960822PubMed

See all 87 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42836780

GET https://conductscience.org/api/papers/v1/42836780/references?page=2